Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

32.75 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 32.75
Bid (Size) 31.17 (1)
Ask (Size) 34.45 (1)
Prev. Close 32.75
Today's Range 32.75 - 32.75
52wk Range 26.47 - 41.61
Shares Outstanding 57,031,297
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) – An Undervalued Stock with Strong Fundamentals
HARMONY BIOSCIENCES (HRMY) is an undervalued pharmaceutical stock with strong profitability, financial health, and growth potential, making it a candidate for value investors. 
Via Chartmill
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) - A Strong Candidate for Affordable Growth Investors
HARMONY BIOSCIENCES (HRMY) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the pharmaceutical... 
Via Chartmill

Performance

YTD
-6.0%
-6.0%
1 Month
-7.5%
-7.5%
3 Month
+16.4%
+16.4%
6 Month
-6.9%
-6.9%
1 Year
+0.6%
+0.6%

More News

Read More
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Potentially Undervalued Stock in the Pharmaceutical Sector
Via Chartmill
Where Harmony Biosciences Hldgs Stands With Analysts
Via Benzinga
Earnings Scheduled For May 6, 2025
Via Benzinga
Harmony Biosciences's Earnings: A Preview
Via Benzinga
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Growth Stock at a Reasonable Valuation
Via Chartmill
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Holdings ([NASDAQ:HRMY](https://www.chartmill.com/stock/quote/HRMY/profile)) – A Strong Growth Stock with Technical Breakout Potential
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Potentially Undervalued Stock with Strong Fundamentals
Via Chartmill
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) - A Strong Candidate for Affordable Growth Investors
Via Chartmill
Deep Dive Into Harmony Biosciences Hldgs Stock: Analyst Perspectives (13 Ratings)
Via Benzinga
Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Affordable Growth Stock
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Affordable Growth Stock Candidate
Via Chartmill
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is not too expensive for the growth it is showing.
Via Chartmill
Breaking Down Harmony Biosciences Hldgs: 13 Analysts Share Their Views
Via Benzinga
Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Friday's pre-market session: top gainers and losers
Via Chartmill
In the world of growth stocks, HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) shines as a value proposition.
Via Chartmill
Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors
From Harmony Biosciences Holdings, Inc.
Via Business Wire

Frequently Asked Questions

Is Harmony Biosciences Holdings, Inc. - Common Stock publicly traded?
Yes, Harmony Biosciences Holdings, Inc. - Common Stock is publicly traded.
What exchange does Harmony Biosciences Holdings, Inc. - Common Stock trade on?
Harmony Biosciences Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Harmony Biosciences Holdings, Inc. - Common Stock?
The ticker symbol for Harmony Biosciences Holdings, Inc. - Common Stock is HRMY on the Nasdaq Stock Market
What is the current price of Harmony Biosciences Holdings, Inc. - Common Stock?
The current price of Harmony Biosciences Holdings, Inc. - Common Stock is 32.75
When was Harmony Biosciences Holdings, Inc. - Common Stock last traded?
The last trade of Harmony Biosciences Holdings, Inc. - Common Stock was at 07/08/25 04:00 PM ET
What is the market capitalization of Harmony Biosciences Holdings, Inc. - Common Stock?
The market capitalization of Harmony Biosciences Holdings, Inc. - Common Stock is 1.87B
How many shares of Harmony Biosciences Holdings, Inc. - Common Stock are outstanding?
Harmony Biosciences Holdings, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.